Ensysce Biosciences (ENSC) Return on Assets (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Return on Assets of 0.01% for Q4 2025, little changed year-over-year from 0.01% in Q4 2024, and up 44.33% quarter-over-quarter from 0.03% in Q3 2025.
Ensysce Biosciences (ENSC) Return on Assets (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Return on Assets for 8 consecutive years, with 0.01% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Assets changed 0.0% year-over-year to 0.01%; the TTM figure through Dec 2025 stood at 0.01% (changed 0.0% YoY), while the FY2024 annual figure was 0.02%, up 1.0% from the prior year.
- Return on Assets climbed to 0.01% in Q4 2025 per ENSC's latest filing, from 0.03% in the prior quarter.
- Across five years, Return on Assets topped out at 0.01% in Q1 2021 and bottomed at 0.72% in Q3 2021.
- Historically, Return on Assets has averaged 0.07% across 5 years, with a median of 0.03% in 2023.
- Annual changes were most pronounced in 2021 — Return on Assets plunged 72 bps — and 2022, when it jumped 70 bps.
- Ensysce Biosciences' Return on Assets stood at 0.09% in 2021, then soared by 61 bps to 0.03% in 2022, then slipped by 5 bps to 0.04% in 2023, then surged by 70 bps to 0.01% in 2024, then sank by 31 bps to 0.01% in 2025.
- Business Quant data shows ENSC's Return on Assets at 0.01% in Q4 2025, 0.03% in Q3 2025, and 0.01% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 0.00% |
| 10 | Ensysce Biosciences | 932,419.66 | -3.38 Mn | - | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.03% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.01% |
| Dec 31, 2024 | -0.01% |
| Sep 30, 2024 | -0.01% |
| Jun 30, 2024 | -0.03% |
| Mar 31, 2024 | -0.03% |
| Dec 31, 2023 | -0.04% |
| Sep 30, 2023 | -0.03% |
| Jun 30, 2023 | -0.03% |
| Mar 31, 2023 | -0.05% |
| Dec 31, 2022 | -0.03% |
| Sep 30, 2022 | -0.02% |
| Jun 30, 2022 | -0.03% |
| Mar 31, 2022 | -0.06% |
| Dec 31, 2021 | -0.09% |
| Sep 30, 2021 | -0.72% |
| Jun 30, 2021 | -0.08% |
| Mar 31, 2021 | -0.01% |